Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.42 |
| ▸ | TTK | P33981 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409493 | 0.85 | PTGS2 (0.48) | TTK | |
| SCHEMBL2180513 | 0.84 | CA1 (0.46) | TTK | |
| SCHEMBL12409243 | 0.82 | TTK (0.57) | FYNTTKADORA3 | |
| SCHEMBL12409495 | 0.79 | PI4KB (0.44) | TTKAURKBAURKA | |
| SCHEMBL12409490 | 0.78 | FYN (0.42) | FYNTTKADORA3PIM1MKNK1 | |
| SCHEMBL12409282 | 0.76 | TTK (0.55) | TTKADORA3 | |
| SCHEMBL12409492 | 0.74 | TTK (0.41) | FYNTTK | |
| SCHEMBL12409244 | 0.73 | TTK (0.68) | TTKADORA3 | |
| SCHEMBL2178350 | 0.72 | CA1 (0.47) | TTK | |
| SCHEMBL12409334 | 0.72 | PI4KB (0.45) | PTK6TTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | FYN 3511/4885PTK6 4129/4885TTK 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.